Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2007 Dec;9(8):888-94.
doi: 10.1111/j.1399-5618.2007.00450.x.

A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder

Joseph Biederman  1 , Eric Mick, Thomas Spencer, Meghan Dougherty, Megan Aleardi, Janet Wozniak
Affiliations
Clinical Trial

A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder

Joseph Biederman et al. Bipolar Disord. 2007 Dec.

Abstract

Objective: To assess the effectiveness and tolerability of ziprasidone for treating pediatric mania.

Methods: This was an eight-week, open-label, prospective study of ziprasidone monotherapy (57.3 +/- 33.9 mg/day) in 21 bipolar youth [manic, mixed, or bipolar not otherwise specified (NOS); 6-17 years old]. Assessments included the Young Mania Rating Scale (YMRS), Clinical Global Impressions-Improvement scale (CGI-I), and Brief Psychiatric Rating Scale (BPRS). Adverse events were assessed through spontaneous self-reports, vital signs, weight monitoring, and laboratory analysis.

Results: Fourteen of the 21 youth (67%) completed the study. Ziprasidone treatment was associated with clinically and statistically significant improvement in mean YMRS scores (-10.8 +/- 8.4, p < 0.0001) and 57% had a CGI-I <or=2 at endpoint. Ziprasidone was well tolerated with no statistically significant increase in body weight (0.6 +/- 0.4 kg, p = 0.2) or QTc interval (-3.7 +/- 4.7, p = 0.5).

Conclusions: Open-label ziprasidone treatment was associated with a significant short-term improvement of symptoms of pediatric bipolar disorder. Future placebo-controlled, double-blind studies are warranted.

PubMed Disclaimer

Publication types